Virginie Bernard
Overview
Explore the profile of Virginie Bernard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3325
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boedec M, Aucouturier C, Cavaille M, Leman R, Castera L, Delhomelle H, et al.
Fam Cancer
. 2025 Feb;
24(1):21.
PMID: 39920402
PTEN Hamartoma Tumor Syndrome (PHTS) is an autosomal dominant disorder characterized by high penetrance and significant phenotypic variability. In most patients, targeted high-throughput sequencing (HTS) approaches enable the detection of...
2.
Berlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, et al.
Cancer Discov
. 2022 Mar;
12(5):1266-1281.
PMID: 35292802
Abstract: MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage...
3.
Cabel L, Aparicio T, Bieche I, Svrcek M, Zaanan A, Afchain P, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-9.
PMID: 35135114
Purpose: Functional studies have demonstrated that some mutations of , which encodes for human epidermal growth factor receptor (HER) 3, are oncogenic via activation of the ErbB family signaling pathway....
4.
Jimenez I, Frouin E, Chicard M, Dehainault C, Le Gall J, Benoist C, et al.
Eur J Cancer
. 2021 Jul;
154:277-287.
PMID: 34298378
Purpose: The analysis of circulating tumor DNA (ctDNA), a fraction of total cell-free DNA (cfDNA), might be of special interest in retinoblastoma patients. Because the accessibility to tumor tissue is...
5.
Bellini A, Potschger U, Bernard V, Lapouble E, Baulande S, Ambros P, et al.
J Clin Oncol
. 2021 Jun;
39(30):3377-3390.
PMID: 34115544
Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied genetic alterations in high-risk (HR) patients on the...
6.
Callens C, Driouch K, Boulai A, Tariq Z, Comte A, Berger F, et al.
Genome Med
. 2021 Mar;
13(1):44.
PMID: 33722295
Background: Prognosis evaluation of advanced breast cancer and therapeutic strategy are mostly based on clinical features of advanced disease and molecular profiling of the primary tumor. Very few studies have...
7.
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, et al.
Nat Commun
. 2020 Aug;
11(1):4053.
PMID: 32792481
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing...
8.
Bellini A, Bessoltane-Bentahar N, Bhalshankar J, Clement N, Raynal V, Baulande S, et al.
Int J Cancer
. 2019 Apr;
145(10):2781-2791.
PMID: 31018240
In neuroblastoma (NB), genetic alterations in chromatin remodeling (CRGs) and epigenetic modifier genes (EMGs) have been described. We sought to determine their frequency and clinical impact. Whole exome (WES)/whole genome...
9.
Cabel L, Decraene C, Bieche I, Pierga J, Bennamoun M, Fuks D, et al.
Cancers (Basel)
. 2019 Mar;
11(3).
PMID: 30901876
This study was designed to monitor circulating tumor DNA (ctDNA) levels during perioperative chemotherapy in patients with non-metastatic gastric adenocarcinoma. Plasma samples were prospectively collected in patients undergoing perioperative chemotherapy...
10.
Coussy F, De Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, et al.
Int J Cancer
. 2019 Mar;
145(7):1902-1912.
PMID: 30859564
Triple-negative breast cancer (TNBC) represents 10% of all breast cancers and is a very heterogeneous disease. Globally, women with TNBC have a poor prognosis, and the development of effective targeted...